Abstract
We present response and survival outcomes of a pivotal phase 2 trial of the antibody-drug conjugate brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant (N = 102) after a median observation period of approximately 3 years.Median overall survival and progression-free survival were estimated at 40.5months and 9.3months, respectively. Improved outcomes were observed in patients who achieved a complete remission (CR) on brentuximab vedotin, with estimated 3-year overall survival and progression-free survival rates of 73% (95% confidence interval [CI]: 57%, 88%) and 58%(95% CI: 41%, 76%), respectively, in this group (medians not reached).Of the 34 patients who obtained CR, 16 (47%) remain progression-free after a median of 53.3 months (range, 29.0 to 56.2 months) of observation; 12 patients remain progression-free without a consolidative allogeneic stem cell transplant. Younger age, good performance status, and lower disease burden at baseline were characteristic of patients who achieved a CR and were favorable prognostic factors for overall survival. These results suggest that a significant proportion of patients who respond to brentuximab vedotin can achieve prolonged disease control.
Original language | English (US) |
---|---|
Pages (from-to) | 1236-1243 |
Number of pages | 8 |
Journal | Blood |
Volume | 125 |
Issue number | 8 |
DOIs | |
State | Published - Feb 19 2015 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology